Lilly Pharmaceuticals ® (Edge Pearl Mono-Injection) obtains listing approval from the State Drug Administration

yesterday (September 4), LillyPharmaceutical(http://(China) announced that the Tudor ® (Ichizhu mono-injection) for the treatment of patients with moderate to severe plaque psoriasis suitable for systematic treatment or phototherapy has been approved by the State Drug AdministrationThe ® (Ichizhu mono-injection) is based on the conditions to accept the overseas 3 clinicaltrial(http://data, and in advance in China obtained the listing approval of overseas clinical urgent need
sage(http://About The ® (Ichizhu mono-injection)Tupaq ® (Ichizhu mono-injection) is an eight IL-17A inhibitors that help patients with psoriasis patients to benefit clinically, and in August 2018, NMPA added Tsouta (Ichizhu mono-injection) to the list of 48 listed overseas clinically urgently needed new drugsBenefiting from this policy, Tuttt® (IchiZhu mono-injection) was approved for listing in China in just 12 monthsAccording to clinical trial Sympathiser-J data, after 16 weeks of treatment with the Tactad ® (Ichizumab) (Ichizumab monoantigen), 40% of patients achieved PASI 100 (i.epsoriasis area and severity index, which is the international medical community's standard for observing plaque area and appearance to assess the condition), and 87% of patients achieved PASI 90, 97% of patients achieved PASI 75As of March 2019, Tuttt® (IchiZhu mono-injection) has been approved for listing in 57 countries and regions around the world